ITM Isotope Technologies Munich SE (ITM), the radiopharmaceutical biotech company, and Grand Pharmaceutical Group Limited (GP) a diversified global pharmaceutical company listed in Hong Kong, have announced that they have entered into an exclusive licensing agreement for GP to develop, manufacture and commercialize ITM’s oncological radiopharmaceutical candidates, ITM-11 (n.c.a. ¹⁷⁷Lu-edotreotide) and ITM-41 (n.c.a. ¹⁷⁷Lu-zoledronate) as well as the diagnostic TOCscan® (⁶⁸Ga-edotreotide) in the territories of mainland China, Hong Kong, Macau and Taiwan.

Under the terms of the agreement, ITM grants GP an exclusive license for the named products in the licensed territories and will support the supply of the pharmaceutical materials needed to conduct clinical and commercial activities. GP will be responsible for the clinical development, regulatory activities and commercialization of these products in the licensed regions. ITM is eligible for a significant upfront payment as well as potential aggregate regulatory and commercial milestone payments totaling up to approximately EUR 520 million in addition to tiered royalties.

To read more please visit:

ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area